
|Videos|July 31, 2020
ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO
Author(s)Alex Delaney-Gesing
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
3
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
4
Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery
5







